By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Proteins are presented in a new report. According to news reporting from Jinzhou, People's Republic of China, by NewsRx journalists, research stated, "Heat-labile enterotoxin subunit B (LTB) is a non-catalytic protein from a pentameric subunit of Escherichia coli. Based on its function of binding specifically to ganglioside GM1 on the surface of cells, a novel nanoparticle (NP) composed of a mixture of bovine serum albumin (BSA) and LTB was designed for targeted delivery of 5-fluorouracil to tumor cells."
The news correspondents obtained a quote from the research from Liaoning Medical University, "BSA-LTB NPs were characterized by determination of their particle size, polydispersity, morphology, drug encapsulation efficiency, and drug release behavior in vitro. The internalization of fluorescein isothiocyanate-labeled BSA-LTB NPs into cells was observed using fluorescent imaging. BSA-LTB NPs presented a narrow size distribution with an average hydrodynamic diameter of approximately 254 +/- 19 nm and a mean zeta potential of approximately -19.95 +/- 0.94 mV. In addition, approximately 80.1% of drug was encapsulated in NPs and released in the biphasic pattern. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay showed that BSA-LTB NPs exhibited higher cytotoxic activity than non-targeted NPs (BSA NPs) in SMMC-7721 cells. Fluorescent imaging results proved that, compared with BSA NPs, BSA-LTB NPs could greatly enhance cellular uptake."
According to the news reporters, the research concluded: "Hence, the results indicate that BSA-LTB NPs could be a potential nanocarrier to improve targeted delivery of 5-fluorouracil to tumor cells via mediation of LTB."
For more information on this research see: Preparation of biocompatible heat-labile enterotoxin subunit B-bovine serum albumin nanoparticles for improving tumor-targeted drug delivery via heatlabile enterotoxin subunit B mediation. International Journal of Nanomedicine, 2014;9():2149-2156. International Journal of Nanomedicine can be contacted at: Dove Medical Press Ltd, PO Box 300-008, Albany, Auckland 0752, New Zealand (see also Proteins).
Our news journalists report that additional information may be obtained by contacting L. Zhao, Liaoning Med Univ, Sch Vet Med, Jinzhou 121000, People's Republic of China. Additional authors for this research include R.J. Su, W.Y. Cui, Y.J. Shi, L.W. Liu and C. Su.
Keywords for this news article include: Asia, Antimetabolites, Antineoplastics, Pharmaceuticals, Jinzhou, Therapy, Enterotoxins, Fluorouracil, Nanoparticle, Blood Proteins, Nanotechnology, Biological Toxins, Acute-Phase Proteins, Bovine Serum Albumin, Drug Delivery Systems, Emerging Technologies, People's Republic of China
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC